Phase I Study Investigating the Safety, Tolerability, PK and Food Effect of BEN8744.

• Sponsor: BenevolentAI Bio (Industry)
• Overall Status: Recruiting
• CT.gov ID: NCT06118385
• Collaborator: (none)
• Enrollment: 108
• Location: 1
• Arms: 18
• Anticipated Duration (Months): 6.8
• Patients Per Site Per Month: 15.8

Study Details

Study Description

Brief Summary

BEN8744 is an experimental new medicine for treating inflammatory bowel diseases such as Ulcerative Colitis.

The study will test single and repeated doses of BEN8744 or placebo by mouth. BEN8744 is a first in human study, so will start with a small dose and the dose will be increased as the study progresses. The goal is to find out its side effects and blood levels when taken by mouth and whether food affects the blood levels.

This is a 3-part study (Parts A, B and C) in up to 108 healthy people, aged 18-65.

Part A, will include 64 participants, single doses of BEN8744 or placebo. They'll take about 2 weeks to finish the study, stay on the ward for 4 nights and 5 days in a row and make 2 outpatient visits.

Part B, will include up to 12 participants, single doses of BEN8744 with and without food. They'll take up to 3 weeks to finish the study, stay on the ward for 4 nights and 5 days in a row on 2 occasions, and make 2 outpatient visits.

Part C will include 32 participants repeat doses of the BEN8744 or placebo for 14 days. They'll take about 4 weeks to complete the study, stay on the ward for 17 nights and 18 days in a row and make 2 outpatient visits.

Condition or Disease	Intervention/Treatment	Phase
Healthy Volunteer Study	Drug: BEN8744; Drug: Matching Placebo	Phase 1

Detailed Description

This first time in human, study will investigate the safety, tolerability, pharmacokinetics (PK) of BEN8744 after single and multiple ascending oral doses in healthy subjects, in both the fed and fasted state. The results of this study will be used to select doses for subsequent studies in patients. This is an exploratory study in healthy volunteers, with no anticipated therapeutic benefit to the participants; involvement of patients, service users or members of the public in the design of the trial is not appropriate.

Primary objectives Part A: To assess the safety and tolerability of single ascending oral doses of BEN8744 in healthy subjects Part B: To characterise the effect of food on the pharmacokinetic profile of at least 1 dose of BEN8744 Part C: To assess the safety and tolerability of multiple ascending oral doses of BEN8744 in healthy subjects

Secondary objectives Part A: To assess the PK profile of BEN8744 after single oral doses in healthy subjects Part B: To assess the safety and tolerability of a single dose of BEN8744 following high-fat food intake relative to fasting conditions in healthy subjects Part C: To assess the PK profile of BEN8744 after repeated oral doses in healthy subjects

Exploratory objective

Part B (and optional in Part C):

To measure BEN8744 in urine and determine renal clearance in healthy subjects. Exploratory characterisation of BEN8744 and its metabolites in plasma, urine, and faeces.

For part A

• 64 subjects, 6 cohorts + 2 optional, 6 active, 2 placebo.

• Subjects will receive a single dose of BEN8744 or placebo, as capsules, after an overnight fast of at least 10 h.

• At each dose level, 6 subjects will receive BEN8744 and 2 will receive matching placebo in an overall ratio of 3:1.

• The starting dose for Group 1 is 2 mg BEN8744 or placebo. It is intended that subsequent cohorts will receive higher doses.

A1- 2mg A2- 6mg A3- 20mg A4- 40mg A5- 80mg A6- 140mg A7 & A8 (optional) tbc

For Part B

• 12 subjects, 1 cohorts + 1 optional, 2 sessions fasted/fed.

• Each subject in Part B will have 2 study sessions (Sessions 1 and 2), in which they will receive a single dose of BEN8744, by mouth.

• Each subject will receive BEN8744 after an overnight fast of at least 10 h in one session, and after an FDA high-fat breakfast (1,013 kcal, 59.2 g fat [of which 28.1 g saturated fat) in the other session; the order will be randomised 1:1.

• A subject's doses will be separated by a washout of at least 7 days (or 5 half-lives as determined in Part A, whichever is longer).

• Subjects dosed on the same day may be dosed at intervals of at least 10 min.

For Part C:

• 32 subjects, 3 cohorts + 1 optional, 6 active, 2 placebo.

• Each subject will receive daily doses of BEN8744 or placebo, by mouth, for 14 days.

• Doses will be taken once or twice daily in the fasted state, unless emerging data indicate they should be taken in the fed state.

• Part C will not start until at least 3 dose levels have been completed in Part A and may also be conducted in parallel with Part B.

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 108 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: The trial will be in 3 parts: Part A will investigate single ascending oral doses of BEN8744; Part B is a 2-way crossover assessment of the effect of food on the PK of BEN8744; and Part C will investigate multiple ascending oral doses of BEN8744The trial will be in 3 parts: Part A will investigate single ascending oral doses of BEN8744; Part B is a 2-way crossover assessment of the effect of food on the PK of BEN8744; and Part C will investigate multiple ascending oral doses of BEN8744
• Masking: Triple (Participant, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Randomised, Double-blind, Placebo-controlled, Phase 1 First-in-human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of Single- and Multiple-ascending Doses of BEN8744 in Healthy Subjects.
• Actual Study Start Date: Aug 30, 2023
• Anticipated Primary Completion Date: Mar 11, 2024
• Anticipated Study Completion Date: Mar 25, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Part A Dose 1 Part A Dose 1 Single dose of 2 mg BEN8744	Drug: BEN8744; Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
Experimental: Part A Dose 2 Part A Dose 2 Single dose of 6 mg BEN8744	Drug: BEN8744; Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
Experimental: Part A Dose 3 Part A Dose 3 Single dose of 20 mg BEN8744	Drug: BEN8744; Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
Experimental: Part A Dose 4 Part A Dose 4 Single dose of 40 mg BEN8744	Drug: BEN8744; Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
Experimental: Part A Dose 5 Part A Dose 5 Single dose of 80 mg BEN8744	Drug: BEN8744; Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
Experimental: Part A Dose 6 Part A Dose 6 Single dose of 140 mg BEN8744	Drug: BEN8744; Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
Experimental: Part A Dose 7 Part A Dose 7 Single dose of BEN8744 (Optional) Dose To Be Determined (TBD)	Drug: BEN8744; Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
Experimental: Part A Dose 8 Part A Dose 8 Single dose of BEN8744 TBD (optional)	Drug: BEN8744; Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
Experimental: Part A placebo Part A placebo Single dose of placebo	Drug: Matching Placebo; Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
Experimental: Part B Dose 1 fed Part B Dose 1 Fed Single dose of BEN8744 TBD after high-fat meal	Drug: BEN8744; Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
Experimental: Part B Dose 1 Fasted Part B Dose 1 Fasted Single dose of BEN8744 TBD after 10 hours fasting	Drug: BEN8744; Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
Experimental: Part B Dose 2 Fed Part B Dose 2 Fed Single dose of BEN8744 TBD after high-fat meal (optional)	Drug: BEN8744; Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
Experimental: Part B Dose 2 Fasted Part B Dose 2 Fasted Single dose of BEN8744 TBD after 10 hours fasting (optional)	Drug: BEN8744; Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
Experimental: Part C Dose 1 Part C Dose 1 14 daily doses of BEN8744 TBD	Drug: BEN8744; Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
Experimental: Part C Dose 2 Part C Dose 2 14 daily doses of BEN8744 TBD	Drug: BEN8744; Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
Experimental: Part C Dose 3 Part C Dose 3 14 daily doses of BEN8744 TBD	Drug: BEN8744; Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
Experimental: Part C Dose 4 Part C Dose 4 14 daily doses of BEN8744 TBD (optional)	Drug: BEN8744; Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
Experimental: Part C placebo Part C placebo 14 daily doses of placebo	Drug: Matching Placebo; Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.

Outcome Measures

Primary Outcome Measures

1. Observer's Assessment of Alertness/Sedation scale (OAAS/S) (Part A only) [Immediately before each PK blood sample up to 72 hours after dosing.]

   In the OAAS/S, the investigator or their delegate will score the subject's level of alertness on a scale of minimum 0 to maximum 5, where 0 is absence of response to stimulus, and 5 is readily responsive to the subject's name in a normal tone.

2. Visual analogue scale (VAS) (Part A only) [Immediately before each PK blood sample up to 72 hours after dosing.]

   In the VAS, subjects will complete a self-reported post-dosing questionnaire. Subjects will be asked to grade their alertness on a linear scale from 0 (very alert) to 100 (very drowsy).

3. Columbia-Suicide Severity Rating Scale (C-SSRS; Part C only) [Day 17 and Day 24 +/-2 days (follow up)]

   The C-SSRS is a suicidal ideation rating scale used to evaluate suicidality. The questionnaire will be administered by the investigator or their delegate. Answers will be listed in a "yes" and "no" format i,e, no score calculated.

4. Cmax (PK Part B) [Day 1 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; on Day 2 (24 and 36 hours); on Day 3 (48 hours); and on Day 4 (72 hours) in each treatment session.]

   Maximum (peak) plasma concentration. Obtained directly from the concentration-time data.

5. tmax (PK Part B) [Day 1 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; on Day 2 (24 and 36 hours); on Day 3 (48 hours); and on Day 4 (72 hours) in each treatment session.]

   Time to reach maximum (peak) plasma concentration. Obtained directly from the concentration-time data.

6. AUC24 (PK Part B) [Day 1 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; on Day 2 (24 and 36 hours); on Day 3 (48 hours); and on Day 4 (72 hours) in each treatment session.]

   Area under the plasma concentration-time curve from time zero to time 24 h.Calculated using the trapezoidal method.

7. AUC72 (PK Part B) [Day 1 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; on Day 2 (24 and 36 hours); on Day 3 (48 hours); and on Day 4 (72 hours) in each treatment session.]

   Area under the plasma concentration-time curve from time zero to time 72 h. Calculated using the trapezoidal method.

8. AUClast (PK Part B) [Day 1 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; on Day 2 (24 and 36 hours); on Day 3 (48 hours); and on Day 4 (72 hours) in each treatment session.]

   Area under the plasma concentration-time curve from time zero to time of last measurable concentration. Calculated using the trapezoidal method.

9. AUCinf (PK Part B) [Day 1 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; on Day 2 (24 and 36 hours); on Day 3 (48 hours); and on Day 4 (72 hours) in each treatment session.]

   Area under the plasma concentration-time curve from time zero to infinity. Calculated using the trapezoidal method for the interval 0 to tlast.

10. %AUCextrap (PK Part B) [Day 1 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; on Day 2 (24 and 36 hours); on Day 3 (48 hours); and on Day 4 (72 hours) in each treatment session.]

    Percentage of AUC∞ extrapolated from tlast to infinity.

11. t1⁄2 (PK Part B) [Day 1 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; on Day 2 (24 and 36 hours); on Day 3 (48 hours); and on Day 4 (72 hours) in each treatment session.]

    Terminal half-life. Calculated from the terminal slope of the log concentration-time curve.

12. Terminal Rate Constant (PK Part B) [Day 1 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; on Day 2 (24 and 36 hours); on Day 3 (48 hours); and on Day 4 (72 hours) in each treatment session.]

    Estimated by linear regression of logarithmically transformed concentration versus time data.

13. CL/F (PK Part B) [Day 1 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; on Day 2 (24 and 36 hours); on Day 3 (48 hours); and on Day 4 (72 hours) in each treatment session.]

    Apparent total clearance from plasma after oral administration.

14. VZ/F (PK Part B) [Day 1 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours; on Day 2 (24 and 36 hours); on Day 3 (48 hours); and on Day 4 (72 hours) in each treatment session.]

    Apparent volume of distribution during terminal phase after non-intravenous administration.

Secondary Outcome Measures

1. Cmax (PK Part A) [Day 1 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 16 hours; on Day 2 (24 and 36 hours); on Day 3 (48 hours); and on Day 4 (72 hours).]

   Maximum (peak) plasma concentration. Obtained directly from the concentration-time data.

2. tmax (PK Part A) [Day 1 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 16 hours; on Day 2 (24 and 36 hours); on Day 3 (48 hours); and on Day 4 (72 hours).]

   Time to reach maximum (peak) plasma concentration. Obtained directly from the concentration-time data.

3. AUC24 (PK Part A) [Day 1 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 16 hours; on Day 2 (24 and 36 hours); on Day 3 (48 hours); and on Day 4 (72 hours).]

   Area under the plasma concentration-time curve from time zero to time 24 h. Calculated using the trapezoidal method.

4. AUC72 (PK Part A) [Day 1 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 16 hours; on Day 2 (24 and 36 hours); on Day 3 (48 hours); and on Day 4 (72 hours).]

   Area under the plasma concentration-time curve from time zero to time 72 h. Calculated using the trapezoidal method.

5. AUClast (PK Part A) [Day 1 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 16 hours; on Day 2 (24 and 36 hours); on Day 3 (48 hours); and on Day 4 (72 hours).]

   Area under the plasma concentration-time curve from time zero to time of last measurable concentration. Calculated using the trapezoidal method.

6. AUCinf (PK Part A) [Day 1 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 16 hours; on Day 2 (24 and 36 hours); on Day 3 (48 hours); and on Day 4 (72 hours).]

   Area under the plasma concentration-time curve from time zero to infinity. Calculated using the trapezoidal method.

7. %AUCextrap (PK Part A) [Day 1 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 16 hours; on Day 2 (24 and 36 hours); on Day 3 (48 hours); and on Day 4 (72 hours).]

   Percentage of AUC∞ extrapolated from tlast to infinity.

8. t1⁄2 (PK Part A) [Day 1 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 16 hours; on Day 2 (24 and 36 hours); on Day 3 (48 hours); and on Day 4 (72 hours).]

   Terminal half-life. Calculated from the terminal slope of the log concentration-time curve.

9. Terminal Rate Constant (PK Part A) [Day 1 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 16 hours; on Day 2 (24 and 36 hours); on Day 3 (48 hours); and on Day 4 (72 hours).]

   Estimated by linear regression of logarithmically transformed concentration versus time data.

10. CL/F (PK Part A) [Day 1 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 16 hours; on Day 2 (24 and 36 hours); on Day 3 (48 hours); and on Day 4 (72 hours).]

    Apparent total clearance from plasma after oral administration.

11. VZ/F (PK Part A) [Day 1 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 16 hours; on Day 2 (24 and 36 hours); on Day 3 (48 hours); and on Day 4 (72 hours).]

    Apparent volume of distribution during terminal phase after non-intravenous administration

12. Observer's Assessment of Alertness/Sedation scale (OAAS/S) (Part B) [Immediately before each PK blood sample up to 72 hours after dosing.]

    In the OAAS/S, the investigator or their delegate will score the subject's level of alertness on a scale of minimum 0 to maximum 5, where 0 is absence of response to stimulus, and 5 is readily responsive to the subject's name in a normal tone.

13. Visual analogue scale (VAS) (Part B) [Immediately before each PK blood sample up to 72 hours after dosing.]

    In the VAS, subjects will complete a self-reported post-dosing questionnaire. Subjects will be asked to grade their alertness on a linear scale from 0 (very alert) to 100 (very drowsy).

14. Cmax (PK Part C) [Once-daily dosing: Days 1 and 14 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 16 hours; on Days 2, 15, 16 and 17. Trough samples will be taken predose on Days 3, 5, 7, 9, 11, and 13.]

    Maximum (peak) plasma concentration.Obtained directly from the concentration-time data.

15. tmax (PK Part C) [Once-daily dosing: Days 1 and 14 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 16 hours; on Days 2, 15, 16 and 17. Trough samples will be taken predose on Days 3, 5, 7, 9, 11, and 13.]

    Time to reach maximum (peak) plasma concentration.Obtained directly from the concentration-time data.

16. Ctrough (PK Part C) [Once-daily dosing: Days 1 and 14 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 16 hours; on Days 2, 15, 16 and 17. Trough samples will be taken predose on Days 3, 5, 7, 9, 11, and 13.]

    Trough plasma concentration. Trough plasma concentration (measured concentration at the end of a dosing interval at steady state [taken directly before next administration]) obtained directly from the concentration-time data.

17. AUCtau (PK Part C) [Once-daily dosing: Days 1 and 14 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 16 hours; on Days 2, 15, 16 and 17. Trough samples will be taken predose on Days 3, 5, 7, 9, 11, and 13.]

    Area under the plasma concentration-time curve during a dosing interval (tau).Calculated using the trapezoidal method.

18. AUClast (PK Part C) [Once-daily dosing: Days 1 and 14 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 16 hours; on Days 2, 15, 16 and 17. Trough samples will be taken predose on Days 3, 5, 7, 9, 11, and 13.]

    Area under the plasma concentration-time curve from time zero to time of last measurable concentration. Calculated using the trapezoidal method

19. AUC72 (PK Part C) [Once-daily dosing: Days 1 and 14 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 16 hours; on Days 2, 15, 16 and 17. Trough samples will be taken predose on Days 3, 5, 7, 9, 11, and 13.]

    Area under the plasma concentration-time curve from time zero to time 72 h.

20. AUCinf (PK Part C) [Once-daily dosing: Days 1 and 14 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 16 hours; on Days 2, 15, 16 and 17. Trough samples will be taken predose on Days 3, 5, 7, 9, 11, and 13.]

    Area under the plasma concentration-time curve from time zero to infinity. Calculated using the trapezoidal method for the interval 0 to tlast.

21. %AUCextrap (PK Part C) [Once-daily dosing: Days 1 and 14 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 16 hours; on Days 2, 15, 16 and 17. Trough samples will be taken predose on Days 3, 5, 7, 9, 11, and 13.]

    Percentage of AUC∞ extrapolated from tlast to infinity.

22. t1⁄2 (PK Part C) [Once-daily dosing: Days 1 and 14 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 16 hours; on Days 2, 15, 16 and 17. Trough samples will be taken predose on Days 3, 5, 7, 9, 11, and 13.]

    Terminal half-life. Calculated from the terminal slope of the log concentration-time curve.

23. Terminal Rate Constant (PK Part C) [Once-daily dosing: Days 1 and 14 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 16 hours; on Days 2, 15, 16 and 17. Trough samples will be taken predose on Days 3, 5, 7, 9, 11, and 13.]

    Estimated by linear regression of logarithmically transformed concentration versus time data

24. CLSS/F (PK Part C) [Once-daily dosing: Days 1 and 14 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 16 hours; on Days 2, 15, 16 and 17. Trough samples will be taken predose on Days 3, 5, 7, 9, 11, and 13.]

    Apparent total clearance from plasma at steady state after non-intravenous administration.

25. VZ/F (PK Part C) [Once-daily dosing: Days 1 and 14 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 16 hours; on Days 2, 15, 16 and 17. Trough samples will be taken predose on Days 3, 5, 7, 9, 11, and 13.]

    apparent volume of distribution after non-intravenous administration calculated at steady state

26. Rac(AUC) (PK Part C) [Once-daily dosing: Days 1 and 14 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 16 hours; on Days 2, 15, 16 and 17. Trough samples will be taken predose on Days 3, 5, 7, 9, 11, and 13.]

    Accumulation ratio for AUC.Calculated from AUCtau at steady state and AUCtau after a single dose.

27. Rac(Cmax) (PK Part C) [Once-daily dosing: Days 1 and 14 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 16 hours; on Days 2, 15, 16 and 17. Trough samples will be taken predose on Days 3, 5, 7, 9, 11, and 13.]

    Accumulation ratio for Cmax. Calculated from Cmax at steady state and Cmax after a single dose.

28. SR(AUC) (PK Part C) [Once-daily dosing: Days 1 and 14 at predose and postdose at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 16 hours; on Days 2, 15, 16 and 17. Trough samples will be taken predose on Days 3, 5, 7, 9, 11, and 13.]

    Stationarity ratio for AUC. Stationarity ratio will be calculated from AUCt at steady state and AUC∞ after single dose.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 65 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

1. Male or female healthy volunteer in good health

2. Aged 18-65 years

3. Body mass index 18.0-30.9 and weight ≥ 50 kg

Exclusion Criteria:

1. Woman who is pregnant or lactating, or pre-menopausal woman who is sexually active and not using a reliable method of contraception

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Hammersmith Medicines Research	London		United Kingdom

Sponsors and Collaborators

• BenevolentAI Bio

Investigators

• Principal Investigator: Denisa Wilkes, Hammersmith Medicine Research

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: BenevolentAI Bio
• ClinicalTrials.gov Identifier: NCT06118385
• Other Study ID Numbers: BB-8744-1001
• First Posted: Nov 7, 2023
• Last Update Posted: Nov 7, 2023
• Last Verified: Oct 1, 2023

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Study Results

No Results Posted as of Nov 7, 2023